查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135404

性功能障礙治療市場：全球市場預測，2026-2032年

Drugs for Sexual Dysfunction Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，性功能障礙治療市場規模將成長至 91.4 億美元，複合年成長率為 8.18%。

主要市場統計數據
基準年 2025 52.7億美元
預計年份：2026年 56.4億美元
預測年份 2032 91.4億美元
複合年成長率 (%) 8.18%

性功能障礙治療：執行摘要

性功能障礙藥物用於治療影響性慾、性喚起、勃起功能、射精及相關性功能障礙的疾病。其使用取決於臨床指南、診斷率、患者就醫意願、安全性考慮以及能否獲得合格的處方醫生。在製定治療策略時，人們越來越重視潛在的心血管、代謝、荷爾蒙、神經、心理和藥物相關因素，而不僅僅是緩解症狀。

臨床整合正在改變治療路徑。

醫療保健格局正朝著更個人化的照護、早期評估合併症以及結合藥物治療、行為介入、諮商和生活方式調整的綜合管理方向發展。監管監督、禁忌症篩檢、藥物安全監測以及對仿冒品和不安全產品的警惕對於保護患者仍然至關重要。線上諮詢和藥局服務雖然具有提高便利性的潛力，但也需要嚴格的身份驗證、處方管理以及持續護理的保障。

人工智慧有助於提高檢測、分診和安全水平。

人工智慧 (AI) 可以輔助創建臨床記錄、對症狀進行分診、篩檢藥物交互作用、支持用藥依從性，並識別可能受益於潛在疾病評估的患者。在研發領域，它可以輔助整合證據、招募臨床試驗受試者、分析治療反應模式。有效實施人工智慧需要代表性的數據、臨床醫生的監督、可解釋的輸出、隱私保護和偏差監控。人工智慧應作為醫療診斷和處方決策的補充，而非替代。

區域洞察：醫療資源取得差異與多樣化的醫療環境

在北美，相對發達的專科醫療保健和數位健康基礎設施與可負擔性、保險和隱私等挑戰並存。在歐洲，報銷制度和處方流程因國家而異，但都受到協調一致的監管標準的影響。亞太地區在醫療保健服務取得、人口老化模式、都市化以及對性健康的文化態度方面有顯著差異。拉丁美洲存在著專科醫生資源匱乏和持續存在的自費障礙。同時，中東的法規環境和社會因素也呈現多樣性。非洲的優先事項包括取得基本藥物、發展基層醫療體系、與公共衛生體系融合、打擊假藥。

區域洞察：政策協調與醫療保健系統能力

東協市場需要採取能夠因應不同監管體系、收入水準和醫療基礎設施的方案。金磚國家成員國在國內生產、公共醫療服務、私人醫療和診斷能力方面存在顯著差異。歐盟雖然受益於監管調整，但在報銷制度和臨床實踐方面仍存在國家差異。七國集團（G7）的醫療體系通常擁有強大的研究基礎設施和專家網路，但也面臨著諸如醫療費用可負擔性、人口老化和公平取得等挑戰。海灣合作理事會（GCC）國家正在投資醫療現代化，其需求受到外籍人口和國家衛生策略的影響。北約成員國的醫療體系各不相同，因此，與聯盟成員資格相比，它們各自的監管、採購和臨床准入條件更為重要。

國家概況：多元化的監管和醫療保健管道

澳洲和加拿大已建立完善的醫療保健體系，但仍面臨地域性醫療服務可近性的挑戰。巴西和墨西哥在專科醫療、經濟負擔和產品品管方面存在顯著的區域差異。中國和印度的特點是患者群體龐大且多元化，以及不斷發展的數位化和監管生態系統。日本、韓國以及法國、德國、義大利、西班牙和英國等歐洲國家在保險報銷、處方規範以及初級和專科醫療的協調方面存在差異。俄羅斯的醫療保健格局受監管、經濟和醫療服務可近性的影響。在美國，專科醫生和遠端醫療普及，但在保險覆蓋範圍、自付費用和醫療服務的連續性方面存在顯著差異。

產業領導者的優先行動

領導者應優先考慮臨床責任導向的用藥途徑，加強實證醫學證據的收集、清晰的藥品標籤、禁忌症教育以及上市後安全監測。應與醫療專業人員和數位服務提供者建立夥伴關係，以保障處方標準和病患隱私。教育和分發應根據當地法規、語言、健康素養和醫療能力進行調整，而非採用一刀切的全球模式。應投資於供應鏈的真實性和品管，並利用真實世界數據來識別用藥依從性障礙和弱勢群體。人工智慧專案應限制範圍，並從可審計的應用案例和可衡量的臨床及安全性結果著手。

調查方法：基於證據的市場評估

本執行摘要基於性功能障礙治療的既定市場範圍，從臨床、監管、技術、人口統計和醫療保健可及性等角度對研究結果進行了整合。該評估框架強調公開檢驗的資訊來源，包括監管公告、臨床指南、同行評審研究、醫療保健系統出版刊物以及國家和地區官方政策文件。本摘要不提供市場估計、預測、市場佔有率或公司特定分析；而是將研究結果針對特定地區、群體和國家進行比較整合。

結論：負責任的進入是進步的關鍵。

該領域未來的發展方向將取決於治療與潛在疾病診斷、以患者為中心的諮詢、安全監測和公平獲取之間的有效整合程度。由於地區和國家差異，在地化至關重要，但負責任地使用數位化工具和人工智慧可以幫助改善就診流程和監測。那些能夠將嚴謹的證據、可靠的供應、合規的監管和可衡量的患者獲益相結合的行業領導者，將更有能力支持更安全、更有效的性健康護理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：性功能障礙治療市場：依藥物類別分類

  • 荷爾蒙療法
    • 雌激素療法
    • 睾酮療法
  • PDE5抑制劑
    • 希愛力（他達拉非）
    • Levitra（伐地那非）
    • Stendra（阿伐那非）
    • 威而鋼（Sildenafil）
  • 外用製劑
    • 奶油
    • 凝膠
    • 軟膏

第8章：性功能障礙治療市場：依給藥途徑分類

  • 注射藥物
    • 海綿體內注射
    • 肌肉內注射
  • 口服
  • 外用

第9章：性功能障礙治療市場：依適應症分類

  • 勃起功能障礙
    • 器質性勃起功能障礙
    • 心理性勃起功能障礙
  • 女性性功能障礙
    • 性慾減退障礙
    • 性喚起障礙

第10章：性功能障礙治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
    • 廠商直銷
    • 第三方所有權
  • 零售藥房

第11章：性功能障礙治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：性功能障礙治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：性功能障礙治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • GlaxoSmithKline plc（GSK）
  • Hims & Hers Health, Inc.
  • Lupin Limited
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SK Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • VIVUS LLC

第16章 主要專家

Product Code: MRR-961F26FD6410

The Drugs for Sexual Dysfunction Market is projected to grow by USD 9.14 billion at a CAGR of 8.18% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.27 billion
Estimated Year [2026] USD 5.64 billion
Forecast Year [2032] USD 9.14 billion
CAGR (%) 8.18%

Drugs for Sexual Dysfunction: Executive Summary

Drugs for sexual dysfunction address conditions affecting sexual desire, arousal, erectile function, ejaculation, and related performance concerns. Their use is shaped by clinical guidelines, diagnosis rates, patient willingness to seek care, safety considerations, and access to qualified prescribers. Treatment decisions increasingly emphasize underlying cardiovascular, metabolic, hormonal, neurological, psychological, and medication-related factors rather than symptom relief alone.

Clinical Integration Is Reshaping Treatment Pathways

The landscape is shifting toward more individualized care, earlier assessment of comorbidities, and combination management involving medicines, behavioral interventions, counseling, and lifestyle changes. Regulatory scrutiny, contraindication screening, pharmacovigilance, and attention to counterfeit or unsafe products remain central to patient protection. Digital consultations and pharmacy services may improve convenience, but they also require robust identity verification, prescribing controls, and continuity of care.

Artificial Intelligence Can Improve Discovery, Triage, and Safety

Artificial intelligence can support clinical documentation, symptom triage, interaction screening, adherence support, and identification of patients who may benefit from evaluation of underlying disease. In research and development, it can assist with evidence synthesis, trial recruitment, and analysis of treatment-response patterns. Effective deployment requires representative data, clinician oversight, explainable outputs, privacy safeguards, and monitoring for bias; AI should complement rather than replace medical diagnosis or prescribing judgment.

Regional Insights: Uneven Access and Distinct Care Contexts

North America combines comparatively developed specialty care and digital-health infrastructure with affordability, insurance, and privacy challenges. Europe is influenced by coordinated regulatory standards alongside differing national reimbursement and prescribing pathways. Asia-Pacific presents substantial diversity in healthcare access, aging patterns, urbanization, and cultural attitudes toward sexual health. Latin America continues to face uneven specialist availability and out-of-pocket barriers, while the Middle East reflects varied regulatory environments and social sensitivities. Africa's priorities include essential-medicine access, primary-care capacity, public-health integration, and protection against falsified products.

Group Insights: Policy Alignment and Health-System Capacity

ASEAN markets require approaches that accommodate differing regulatory systems, income levels, and healthcare infrastructure. BRICS members span major differences in domestic production, public provision, private care, and diagnostic capacity. The European Union benefits from regulatory coordination but retains national variation in reimbursement and clinical practice. G7 systems generally have stronger research and specialist networks, while still addressing affordability, aging populations, and equitable access. GCC countries are investing in healthcare modernization, with demand shaped by expatriate populations and national health strategies. NATO members represent diverse health systems, making alliance membership less informative than national regulation, procurement, and clinical access conditions.

Country Insights: Diverse Regulatory and Care Pathways

Australia and Canada combine established healthcare systems with geographic access challenges. Brazil and Mexico face substantial regional variation in specialist care, affordability, and product quality oversight. China and India are characterized by large, diverse patient populations and evolving digital and regulatory ecosystems. Japan, South Korea, and the European countries of France, Germany, Italy, Spain, and the United Kingdom differ in reimbursement, prescribing norms, and integration between primary and specialist care. Russia's treatment environment is shaped by regulatory, economic, and healthcare-access conditions. The United States has broad specialist and telehealth availability but significant variation in coverage, out-of-pocket costs, and care continuity.

Action Priorities for Industry Leaders

Leaders should prioritize clinically responsible access by strengthening evidence generation, clear labeling, contraindication education, and post-market safety monitoring. Build partnerships with healthcare professionals and digital providers that preserve prescribing standards and patient privacy. Tailor education and distribution to local regulations, language, health literacy, and care capacity rather than applying a uniform global model. Invest in supply-chain authentication and quality controls, and use real-world evidence to identify adherence barriers and underserved populations. AI initiatives should begin with narrowly defined, auditable use cases and measurable clinical-safety outcomes.

Research Methodology: Evidence-Led Market Assessment

This executive summary uses the defined market scope of drugs for sexual dysfunction and organizes findings across clinical, regulatory, technological, demographic, and healthcare-access dimensions. The assessment framework emphasizes publicly verifiable sources such as regulatory communications, clinical guidelines, peer-reviewed research, health-system publications, and official country or regional policy documents. Insights are synthesized comparatively across the specified regions, groups, and countries, without presenting market estimates, market shares, forecasts, or company-specific analysis.

Conclusion: Responsible Access Will Define Progress

The sector's direction will be determined by how effectively treatment is integrated with diagnosis of underlying conditions, patient-centered counseling, safety oversight, and equitable access. Regional and country differences make localization essential, while digital tools and AI can improve navigation and monitoring when governed responsibly. Industry leaders that combine rigorous evidence, trusted supply, compliant delivery, and measurable patient benefit will be best positioned to support safer and more effective sexual-health care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drugs for Sexual Dysfunction Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Hormone Therapy
    • 7.2.1. Estrogen Therapy
    • 7.2.2. Testosterone Therapy
  • 7.3. Pde5 Inhibitors
    • 7.3.1. Cialis (Tadalafil)
    • 7.3.2. Levitra (Vardenafil)
    • 7.3.3. Stendra (Avanafil)
    • 7.3.4. Viagra (Sildenafil)
  • 7.4. Topical Agents
    • 7.4.1. Creams
    • 7.4.2. Gels
    • 7.4.3. Ointments

8. Drugs for Sexual Dysfunction Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intracavernosal Injection
    • 8.2.2. Intramuscular Injection
  • 8.3. Oral
  • 8.4. Topical

9. Drugs for Sexual Dysfunction Market, by Indication

  • 9.1. Introduction
  • 9.2. Erectile Dysfunction
    • 9.2.1. Organic Erectile Dysfunction
    • 9.2.2. Psychogenic Erectile Dysfunction
  • 9.3. Female Sexual Dysfunction
    • 9.3.1. Hypoactive Sexual Desire Disorder
    • 9.3.2. Sexual Arousal Disorder

10. Drugs for Sexual Dysfunction Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
    • 10.3.1. Manufacturer-Owned
    • 10.3.2. Third-Party Owned
  • 10.4. Retail Pharmacy

11. Drugs for Sexual Dysfunction Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Drugs for Sexual Dysfunction Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Drugs for Sexual Dysfunction Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Aurobindo Pharma Limited
  • 15.2. Bayer AG
  • 15.3. Cipla Limited
  • 15.4. Dr. Reddy's Laboratories Ltd.
  • 15.5. Eli Lilly and Company
  • 15.6. Endo International plc
  • 15.7. Futura Medical plc
  • 15.8. GlaxoSmithKline plc (GSK)
  • 15.9. Hims & Hers Health, Inc.
  • 15.10. Lupin Limited
  • 15.11. Petros Pharmaceuticals, Inc.
  • 15.12. Pfizer Inc.
  • 15.13. Sanofi S.A.
  • 15.14. SK Inc.
  • 15.15. Sun Pharmaceutical Industries Ltd.
  • 15.16. Teva Pharmaceutical Industries Ltd.
  • 15.17. Viatris Inc.
  • 15.18. VIVUS LLC

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Drugs for Sexual Dysfunction Market, Years Considered for the Study
  • FIGURE 2. Global Drugs for Sexual Dysfunction Market, Research Design
  • FIGURE 3. Global Drugs for Sexual Dysfunction Market, Research Framework
  • FIGURE 4. Global Drugs for Sexual Dysfunction Market, Data Triangulation
  • FIGURE 5. Global Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Drugs for Sexual Dysfunction Market Size, by Drug Class, 2025 vs 2032 (%)
  • FIGURE 7. Global Drugs for Sexual Dysfunction Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Drugs for Sexual Dysfunction Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 11. Global Drugs for Sexual Dysfunction Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Drugs for Sexual Dysfunction Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Drugs for Sexual Dysfunction Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Drugs for Sexual Dysfunction Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Drugs for Sexual Dysfunction Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Drugs for Sexual Dysfunction Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Drugs for Sexual Dysfunction Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Drugs for Sexual Dysfunction Market Segmentation & Coverage
  • TABLE 2. Global Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 4. Global Hormone Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Hormone Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Hormone Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Estrogen Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Estrogen Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Estrogen Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Testosterone Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Testosterone Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Testosterone Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Pde5 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Pde5 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Pde5 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Cialis (Tadalafil) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Cialis (Tadalafil) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Cialis (Tadalafil) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Levitra (Vardenafil) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Levitra (Vardenafil) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Levitra (Vardenafil) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Stendra (Avanafil) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Stendra (Avanafil) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Stendra (Avanafil) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Viagra (Sildenafil) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Viagra (Sildenafil) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Viagra (Sildenafil) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Topical Agents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Topical Agents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Topical Agents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Creams Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Creams Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Creams Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Gels Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Gels Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Gels Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Ointments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Ointments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Ointments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 41. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Intracavernosal Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Intracavernosal Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Intracavernosal Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Topical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Topical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Topical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 57. Global Erectile Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Erectile Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Erectile Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Organic Erectile Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Organic Erectile Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Organic Erectile Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Psychogenic Erectile Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Psychogenic Erectile Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Psychogenic Erectile Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Female Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Female Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Female Sexual Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Hypoactive Sexual Desire Disorder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Hypoactive Sexual Desire Disorder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Hypoactive Sexual Desire Disorder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Sexual Arousal Disorder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Sexual Arousal Disorder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Sexual Arousal Disorder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 76. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Manufacturer-Owned Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Manufacturer-Owned Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Manufacturer-Owned Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global Third-Party Owned Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Global Third-Party Owned Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 87. Global Third-Party Owned Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 88. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 98. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 104. North America Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. North America Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 106. North America Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 107. North America Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 108. North America Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 109. North America Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 110. North America Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 111. North America Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 112. North America Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 113. North America Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 114. North America Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. North America Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 116. Latin America Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. Latin America Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 118. Latin America Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 119. Latin America Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 120. Latin America Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 121. Latin America Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 122. Latin America Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 123. Latin America Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 124. Latin America Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 125. Latin America Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 126. Latin America Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 127. Latin America Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 128. Europe Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 129. Europe Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 130. Europe Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 131. Europe Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 132. Europe Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 133. Europe Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 134. Europe Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 135. Europe Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 136. Europe Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 137. Europe Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 138. Europe Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 139. Europe Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 140. Middle East Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 141. Middle East Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 142. Middle East Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 143. Middle East Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 144. Middle East Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 145. Middle East Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 146. Middle East Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 147. Middle East Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. Middle East Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 149. Middle East Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 150. Middle East Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 151. Middle East Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 152. Africa Drugs for Sexual Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Africa Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 154. Africa Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 155. Africa Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 156. Africa Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 157. Africa Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 158. Africa Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 159. Africa Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 160. Africa Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 161. Africa Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 162. Africa Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 163. Africa Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 164. Global Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. ASEAN Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 166. ASEAN Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 167. ASEAN Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 168. ASEAN Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 169. ASEAN Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 170. ASEAN Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 171. ASEAN Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 172. ASEAN Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 173. ASEAN Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 174. ASEAN Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 175. ASEAN Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 176. ASEAN Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 177. GCC Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 178. GCC Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 179. GCC Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 180. GCC Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 181. GCC Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 182. GCC Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 183. GCC Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 184. GCC Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 185. GCC Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 186. GCC Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 187. GCC Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 188. GCC Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 189. European Union Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 190. European Union Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 191. European Union Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 192. European Union Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 193. European Union Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 194. European Union Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. European Union Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 196. European Union Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 197. European Union Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 198. European Union Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 199. European Union Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. European Union Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 201. BRICS Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 202. BRICS Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 203. BRICS Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 204. BRICS Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 205. BRICS Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 206. BRICS Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 207. BRICS Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 208. BRICS Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 209. BRICS Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 210. BRICS Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 211. BRICS Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 212. BRICS Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 213. G7 Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 214. G7 Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 215. G7 Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 216. G7 Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 217. G7 Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 218. G7 Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 219. G7 Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 220. G7 Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. G7 Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 222. G7 Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 223. G7 Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 224. G7 Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 225. NATO Drugs for Sexual Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 226. NATO Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 227. NATO Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 228. NATO Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 229. NATO Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 230. NATO Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 231. NATO Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 232. NATO Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 233. NATO Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 234. NATO Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 235. NATO Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 236. NATO Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 237. Global Drugs for Sexual Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 238. United States Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 239. United States Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 240. United States Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 241. United States Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 242. United States Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 243. United States Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. United States Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 245. United States Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 246. United States Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 247. United States Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 248. United States Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 249. United States Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 250. Canada Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 251. Canada Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 252. Canada Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 253. Canada Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 254. Canada Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 255. Canada Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 256. Canada Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 257. Canada Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 258. Canada Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 259. Canada Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 260. Canada Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. Canada Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 262. Mexico Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 263. Mexico Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 264. Mexico Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 265. Mexico Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 266. Mexico Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 267. Mexico Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 268. Mexico Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 269. Mexico Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 270. Mexico Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 271. Mexico Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 272. Mexico Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 273. Mexico Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 274. Brazil Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 275. Brazil Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 276. Brazil Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 277. Brazil Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 278. Brazil Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 279. Brazil Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 280. Brazil Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 281. Brazil Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 282. Brazil Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 283. Brazil Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 284. Brazil Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 285. Brazil Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 286. United Kingdom Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 287. United Kingdom Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 288. United Kingdom Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 289. United Kingdom Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 290. United Kingdom Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 291. United Kingdom Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 292. United Kingdom Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 293. United Kingdom Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 294. United Kingdom Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 295. United Kingdom Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 296. United Kingdom Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 297. United Kingdom Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 298. Germany Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 299. Germany Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 300. Germany Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 301. Germany Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 302. Germany Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 303. Germany Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 304. Germany Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 305. Germany Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 306. Germany Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 307. Germany Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 308. Germany Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 309. Germany Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 310. France Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 311. France Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 312. France Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 313. France Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 314. France Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 315. France Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. France Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 317. France Drugs for Sexual Dysfunction Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 318. France Drugs for Sexual Dysfunction Market Size, by Erectile Dysfunction, 2017-2032 (USD Million)
  • TABLE 319. France Drugs for Sexual Dysfunction Market Size, by Female Sexual Dysfunction, 2017-2032 (USD Million)
  • TABLE 320. France Drugs for Sexual Dysfunction Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 321. France Drugs for Sexual Dysfunction Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 322. Russia Drugs for Sexual Dysfunction Market Size, 2017-2032 (USD Million)
  • TABLE 323. Russia Drugs for Sexual Dysfunction Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 324. Russia Drugs for Sexual Dysfunction Market Size, by Hormone Therapy, 2017-2032 (USD Million)
  • TABLE 325. Russia Drugs for Sexual Dysfunction Market Size, by Pde5 Inhibitors, 2017-2032 (USD Million)
  • TABLE 326. Russia Drugs for Sexual Dysfunction Market Size, by Topical Agents, 2017-2032 (USD Million)
  • TABLE 327. Russia Drugs for Sexual Dysfunction Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 328. Russia Drugs for Sexual Dysfunction Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 329. Russia Drugs for Sexual Dysfunction Market Size, by Indication,